Moreover, not all patients had available biomarker data, such as amyloid and tau imaging, which restricted our ability to fully investigate the possible relationship with molecular underpinnings of the observed olfactory deficits and brain atrophy. The gene discussed is MAPT; the disease is Brain atrophy.